Lantheus Holdings, Inc. $LNTH Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 22.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 110,496 shares of the medical equipment provider’s stock after selling 31,821 shares during the quarter. Legal & General Group Plc owned about 0.17% of Lantheus worth $7,354,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Lantheus by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares during the period. M&T Bank Corp acquired a new stake in Lantheus in the 4th quarter valued at approximately $370,950,000. TD Asset Management Inc increased its position in Lantheus by 25.0% in the 3rd quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock valued at $40,568,000 after acquiring an additional 158,358 shares during the period. William Blair Investment Management LLC increased its position in Lantheus by 46.7% in the 3rd quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider’s stock valued at $29,475,000 after acquiring an additional 183,059 shares during the period. Finally, Mackenzie Financial Corp increased its position in Lantheus by 0.6% in the 3rd quarter. Mackenzie Financial Corp now owns 501,593 shares of the medical equipment provider’s stock valued at $25,727,000 after acquiring an additional 2,950 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LNTH. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Truist Financial restated a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Stock Down 1.8%

Shares of LNTH stock opened at $100.98 on Friday. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $104.00. The stock has a market cap of $6.57 billion, a PE ratio of 24.33 and a beta of -0.03. The business’s fifty day moving average is $88.01 and its 200-day moving average is $74.96. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company’s revenue was up 1.2% compared to the same quarter last year. During the same period last year, the company posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts expect that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.